Fabio Ciceri
A5026667594- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- CAR-T cell therapy research
- Chronic Myeloid Leukemia Treatments
- Immune Cell Function and Interaction
- Virus-based gene therapy research
- COVID-19 Clinical Research Studies
- T-cell and B-cell Immunology
- Cytomegalovirus and herpesvirus research
- Polyomavirus and related diseases
- Renal Transplantation Outcomes and Treatments
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Long-Term Effects of COVID-19
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Neutropenia and Cancer Infections
- SARS-CoV-2 and COVID-19 Research
- Immunotherapy and Immune Responses
- Cancer Genomics and Diagnostics
- Transplantation: Methods and Outcomes
- CNS Lymphoma Diagnosis and Treatment
- Immune cells in cancer
- RNA Interference and Gene Delivery
Vita-Salute San Raffaele University
2016-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2016-2025
Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele
2016-2025
San Raffaele University of Rome
2016-2025
IRCCS Ospedale San Raffaele
2016-2025
Mylan (South Africa)
2023-2025
The San Raffaele Telethon Institute for Gene Therapy
2012-2024
Azienda Sanitaria Unità Locale di Reggio Emilia
2024
IRCCS Humanitas Research Hospital
2024
University Foundation
2023
Interindividual clinical variability in the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is vast. We report that at least 101 987 patients with life-threatening disease 2019 (COVID-19) pneumonia had neutralizing immunoglobulin G (IgG) autoantibodies (auto-Abs) against interferon-ω (IFN-ω) (13 patients), 13 types IFN-α (36), or both (52) onset critical disease; a few also auto-Abs other three type I IFNs. The neutralize ability corresponding IFNs to block...
All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies treatment arsenic trioxide or without ATRA have shown high efficacy and reduced hematologic toxicity.We conducted a phase 3, multicenter trial comparing plus patients APL classified as low-to-intermediate risk (white-cell count, ≤10×10(9) per liter). Patients were randomly assigned to receive either induction consolidation...
Metachromatic leukodystrophy (MLD) is an inherited lysosomal storage disease caused by arylsulfatase A (ARSA) deficiency. Patients with MLD exhibit progressive motor and cognitive impairment die within a few years of symptom onset. We used lentiviral vector to transfer functional ARSA gene into hematopoietic stem cells (HSCs) from three presymptomatic patients who showed genetic, biochemical, neurophysiological evidence late infantile MLD. After reinfusion the gene-corrected HSCs, extensive...
Patients with relapsed or refractory acute myeloid leukemia (AML) mutations in the FMS-like tyrosine kinase 3 gene (FLT3) infrequently have a response to salvage chemotherapy. Gilteritinib is an oral, potent, selective FLT3 inhibitor single-agent activity FLT3-mutated AML.In phase trial, we randomly assigned adults AML 2:1 ratio receive either gilteritinib (at dose of 120 mg per day) The two primary end points were overall survival and percentage patients who had complete remission full...
Wiskott-Aldrich syndrome (WAS) is an inherited immunodeficiency caused by mutations in the gene encoding WASP, a protein regulating cytoskeleton. Hematopoietic stem/progenitor cell (HSPC) transplants can be curative, but, when matched donors are unavailable, infusion of autologous HSPCs modified ex vivo therapy alternative approach. We used lentiviral vector functional WASP to genetically correct from three WAS patients and reinfused cells after reduced-intensity conditioning regimen. All...
We investigated the long-term outcome of gene therapy for severe combined immunodeficiency (SCID) due to lack adenosine deaminase (ADA), a fatal disorder purine metabolism and immunodeficiency.
Mortality of patients with coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS), and systemic inflammation is high. In areas pandemic outbreak, the number can exceed maximum capacity intensive care units (ICUs), and, thus, these individuals often receive non-invasive ventilation outside ICU. Effective treatments for this population are needed urgently. Anakinra a recombinant interleukin-1 receptor antagonist that might be beneficial in patient population.We...
Circulating autoantibodies (auto-Abs) neutralizing high concentrations (10 ng/mL, in plasma diluted 1 to 10) of IFN-α and/or -ω are found about 10% patients with critical COVID-19 pneumonia, but not subjects asymptomatic infections. We detect auto-Abs 100-fold lower, more physiological, (100 pg/mL, 1/10 dilutions plasma) 13.6% 3,595 COVID-19, including 21% 374 > 80 years, and 6.5% 522 severe COVID-19. These antibodies also detected 18% the 1,124 deceased (aged 20 days-99 years; mean: 70...
Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), is a potentially life threatening complication that can develop after hematopoietic cell transplantation. Although SOS/VOD progressively resolves within few weeks in most patients, the severe forms result multi-organ dysfunction and are associated with high mortality rate (>80%). Therefore, careful attention must be paid to allow an early detection of SOS/VOD, particularly drugs have now proven effective...
We suggest the use of MicroCLOTS (microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome) as a new name for severe pulmonary coronavirus disease 2019 (COVID-19). hypothesise that, in predisposed individuals, alveolar viral damage is followed by an inflammatory reaction and microvascular thrombosis. This progressive endothelial syndrome may also involve bed brain other vital organs, leading to multiple organ failure death. Future steps understanding identification...
Transplantation of hematopoietic stem cells from partially matched family donors is a promising therapy for patients who have hematologic cancer and are at high risk relapse. The donor T-cell infusions associated with such transplantation can promote post-transplantation immune reconstitution control residual disease.
Abstract Understanding how antibody responses to SARS-CoV-2 evolve during infection may provide important insight into therapeutic approaches and vaccination for COVID-19. Here we profile the of 162 COVID-19 symptomatic patients in COVID-BioB cohort followed longitudinally up eight months from symptom onset find neutralization, as well antibodies either recognizing spike antigens nucleoprotein, or specific S2 antigen seasonal beta-coronaviruses hemagglutinin H1N1 flu virus. The presence...